Pancreatic Cancer Research

ResearcherDaegu Catholic UniversityActive in the last 2 years

Ho Gak Kim

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3365-1662; OpenAlex author ID A5072121395. Sources: ClinicalTrials.gov.

Their work

Papers
6 (first author 1, last author 0)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
0
Collaborators
45
Papers, trials and grants by year

2007: 1 trial · 2008: none · 2009: none · 2010: none · 2011: none · 2012: none · 2013: none · 2014: none · 2015: 1 trial · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: 3 papers

Papers 6

  1. Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin leve… Co-author DOI 10.1038/s41416-023-02474-w↗
  2. Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum … Co-author DOI 10.1038/s41416-023-02520-7↗
  3. Efficacy and Toxicity of Palliative Chemotherapy in Elderly Patients With Advanced Pancreatic Cancer. First author DOI 10.1097/mpa.0000000000002299↗
  4. Venous Thromboembolism in Patients with Advanced Pancreatic Cancer Receiving Palliative Chemotherapy: Incidence and Effect on Prognosis. Co-author DOI 10.4166/kjg.2022.137↗
  5. Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer. Co-author DOI 10.4251/wjgo.v10.i12.505↗
  6. A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreati… Co-author DOI 10.1097/md.0000000000005702↗

Trials 2

  1. A Phase III Study to Assess the Efficacy and Safety of GV1001-Gem/Cap vs Gem/Cap in Pancreatic Cancer Patients Principal investigator NCT02854072↗
  2. Patency and Safety of the Drug Eluting Covered Biliary Stent Comparing to the Common Covered Biliary Stent Principal investigator NCT01512563↗

Closest collaborators

The 25 strongest of 45 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jimin Han · 2 shared papers, 2023–2024 · strength 0.63
  2. Han Taek Jeong · 2 shared papers, 2023–2024 · strength 0.63
  3. Ho Soon Choi · 3 shared papers, 1 shared trial, 2015–2024 · strength 0.44
  4. Yong‐Tae Kim · 3 shared papers, 1 shared trial, 2015–2024 · strength 0.44
  5. Hong Sik Lee · 2 shared papers, 1 shared trial, 2015–2024 · strength 0.39
  6. Eun Kwang Choi · 2 shared papers, 1 shared trial, 2015–2024 · strength 0.39
  7. Seung Ok Lee · 2 shared papers, 1 shared trial, 2015–2024 · strength 0.39
  8. Young Woo Choi · 2 shared papers, 1 shared trial, 2015–2024 · strength 0.39
  9. Si Young Song · 3 shared papers, 2017–2024 · strength 0.38
  10. Dong Uk Kim · 3 shared papers, 2017–2024 · strength 0.38
  11. Chang‐Hwan Park · 2 shared papers, 2024 · strength 0.33
  12. Jae Woo Kim · 2 shared papers, 2024 · strength 0.33
  13. Eui Joo Kim · 2 shared papers, 2024 · strength 0.33
  14. Mi‐Suk Park · 2 shared papers, 2024 · strength 0.33
  15. Y. Choi · 2 shared papers, 2024 · strength 0.33
  16. Jung Hyun Jo · 2 shared papers, 2024 · strength 0.33
  17. Hyungsik Roger Moon · 2 shared papers, 2024 · strength 0.33
  18. Woo Jin Lee · 2 shared papers, 2024 · strength 0.33
  19. Kwang Hyuck Lee · 1 shared paper, 1 shared trial, 2015–2024 · strength 0.23
  20. Kwang Hyuck Lee · 1 shared paper, 2024 · strength 0.16
  21. Moon Jae Chung · 2 shared papers, 2017–2018 · strength 0.13
  22. Sang Hyub Lee · 2 shared papers, 2017–2018 · strength 0.13
  23. Seungmin Bang · 2 shared papers, 2017–2018 · strength 0.13
  24. Jun Kyu Lee · 1 shared paper, 2018 · strength 0.08
  25. Jong Jin Hyun · 1 shared paper, 2018 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.